Nonimmune hydrops fetalis: modern principles of diagnosis and treatment

1. Norton M.E., Chauhan S.P., Dashe J.S. Society for Maternal-Fetal Medicine (SMFM) clinical guideline No.7: nonimmune hydrops fetalis. Am. J. Obstet. Gynecol. 2015; 212(2): 127-39. doi: 10.1016 / j.ajog.2014.12.018
2. Ota S., Sahara J., Mabuchi A., Yamamoto R., Ishii K., Mitsuda N. Perinatal and one-year outcomes of non-immune hydrops fetalis by etiology and age at diagnosis. J. Obstet. Gynaecol. Res. 2015; 42(4): 385-91. doi: 10.1055 / s-0037-1603890
3. Hartge D.R., Weichert J., Gembicki M., Krapp M. Confirmation of etiology in fetal hydrops by sonographic evaluation of fluid allocation patterns. Eur. J. Obstet. Gynecol. Reprod. Biol. 2015; 195: 128-32. doi: 10.1016/ j.ejogrb.2015.09.006
4. Brock W.W., Bradshaw W.T. Congenital chylothorax. Adv. Neonatal Care. 2016; 16(2): 114-23. DOI: 10,1097 / ANC.0000000000000257
5. Ballantyne J.W. The Diseases and deformities of the fetus. Edinburgh: Oliver & Boyd; 1892.
6. Ng Z.M., Seet M.J., Erng M.N., Buendia F., Chang A.S., Sriram B. Nonimmune hydrops fetalis in a childrens hospital: a six-year series. Singapore Med. J. 2013; 54(9): 487-90.
7. Fukushima K., Morokuma S., Fujita Y., Tsukimori K., Satoh S., Ochiai M. et al. Short-term and long-term outcomes of 214 cases of non-immune hydrops fetalis. Early Hum. Dev. 2011; 87(8): 571-5. doi: 10.1016/j.earlhumdev.2011.04.015
8. Milunsky A. Genetic disorders of the fetus: diagnosis, prevention and treatment. 5th ed. Baltimore: John Hopkins University Press, 2004.
9. Bellini C., Donarini G., Paladini D., Calevo M.G., Bellini T., Ramenghi L.A., Hennekam R.C. Etiology of non-immune hydrops fetalis: an update. Am. J. Med. Genet. A. 2015; 167(5): 1082-8. doi: 10.1002 / ajmg.a.36988.
10. Laterre M., Bernard P., Vikkula M., Sznajer Y. Improved diagnosis in non-immune hydrops fetalis using a standardized algorithm. Prenat. Diagn. 2018; 38(5): 337-43. doi: 10.1002 / pd.5243
11. Suwanrath-Kengpol C., Kor-anantakul O., Suntharasajet T., Leetanapon R. Etiology and outcome of non-immune hydrops fetalis in southern Thailand. Gynecol. Obstet. Invest. 2005; 59(3): 134-7. DOI: 10,1159 / 000082997
12. Ratanasiri T., Komwilaisak R., Sittivech A., Kleebkeawet P., Seejorn K. Incidence, causes and pregnancy outcomes of hydrops fetalis at Srinagarind Hospital, 1996-2005: a 10-year review. J. Med. Assoc. Thai. 2009; 92(5): 594-9. doi:10.1111/jog.12922
13. Yang Y.H., Teng R.J., Tang J.R., Yau K.I., Huang L.H., Hsieh F.J. Etiology and outcome of hydrops fetalis. J. Formos. Med. Assoc. 1998; 97(1): 16-20.PMID: 9481059
14. Ismail K.M., Martin W.L., Ghosh S., Whittle M.J., Kilby M.D. Etiology and outcome of hydrops fetalis. J. Matern. Fetal Med. 2001; 10(3): 175-81.
15. Heinonen S., Ryynanen M., Kirkinen P. Etiology and outcome of second trimester non-immunologic fetal hydrops. Acta Obstet. Gynecol. Scand. 2000; 79(1): 15-8. PMID: 10646810
16. Liao C., Wei J., Li Q., Li J., Li L., Li D. Nonimmune hydrops fetalis diagnosed during the second half of pregnancy in Southern China. Fetal Diagn. Ther. 2007; 22(4): 302-5. DOI: 10,1159 / 000100796
17. Anandakumar C., Biswas A., Wong Y.C., Chia D., Annapoorna V., Arulkumaran S., Ratnam S. Management of non-immune hydrops: 8 years’ experience. Ultrasound Obstet. Gynecol. 1996; 8(3): 196-200. DOI: 10,1046 / j.1469-0705.1996.08030196.x
18. Désilets V., De Bie I., Audibert F. No. 363-investigation and management of non-immune fetal hydrops. J. Obstet. Gynaecol. Can. 2018; 40(8): 1077-90. doi: 10.1016 / j.jogc.2017.12.011.
19. Lindenburg I.T., van Kamp I.L., Oepkes D. Intrauterine blood transfusion: current indications and associated risks. Fetal Diagn. Ther. 2014; 36(4): 263-71. doi: 10.1159 / 000362812
20. Sudrié-Arnaud B., Marguet F., Patrier S., Martinovic J., Louillet F., Broux F. et al. Metabolic causes of nonimmune hydrops fetalis: A next-generation sequencing panel as a first-line investigation. Clin. Chim. Acta. 2018; 481: 1-8. doi: 10.1016 /j.cca.2018.02.023
21. Im S.S., Rizos N., Joutsi P., Shime J., Benzie R.J. Nonimmunologic hydrops fetalis. Am. J. Obstet. Gynecol. 1984; 148(5): 566-9. DOI: 10.1016 / 0002-9378 (84) 90749-х
22. Chon A.H., Chmait H.R., Korst L.M., Llanes A., Ouzounian J.G., Chmait R.H. Long-term outcomes after thoracoamniotic shunt for pleural effusions with secondary hydrops. J. Surg. Res. 2019; 233: 304-9. doi: 10.1016 /j.jss.2018.08.022.
23. Nakayama H., Kukita J., Hikino S., Nakano H., Hara T. Long-term outcome of 51 liveborn neonates with non-immune hydrops fetalis. Acta Paediatr. 1999; 88: 24-8. DOI: 10,1080 / 08035259950170547
24. Smoleniec J., James D. Predictive value of pleural effusions in fetal hydrops. Fetal Diagn. Ther. 1995; 10: 95-100. DOI: 10,1159 / 000264213
25. Liu C.A., Huang H.C., Chou Y.Y. Retrospective analysis of 17 liveborn neonates with hydrops fetalis. Chang Gung Med. J. 2002; 25(12): 826-31.PMID: 12635839
26. Dorsi M., Giuseppi A., Lesage F., Stirnemann J., De Saint Blanquat L.,Nicloux M. et al. Prenatal factors associated with neonatal survival of infants with congenital chylothorax. J. Perinatol. 2018; 38(1): 31-4. https://doi.org/10.1002/uog.2733
27. Wilson R.D., Baxter J.K., Johnson M.P., King M., Kasperski S., Crombleholme T.M. et al. Thoracoamniotic shunts: fetal treatment of pleural effusions and congenital cystic adenomatoid malformations. Fetal Diagn. Ther. 2004; 19(5): 413-20. DOI: 10,1159 / 000078994
28. Schrey S., Kelly E.N., Langer J.C., Davies G.A., Windrim R.,Seaward P.G., Ryan G. Fetal thoracoamniotic shunting for large macrocystic congenital cystic adenomatoid malformations of the lung. Ultrasound Obstet. Gynecol. 2012; 39(5): 515-20. doi: 10.1002 / uog.11084
29. Yinon Y., Grisaru-Granovsky S., Chaddha V., Windrim R., Seaward P.G., Kelly E.N. et al. Perinatal outcome following fetal chest shunt insertion for pleural effusion. Ultrasound Obstet. Gynecol. 2010; 36(1): 58-64. doi: 10.1002 /uog.7507
30. Simpson L.L.; Society for Maternal-Fetal Medicine. Twin-twin transfusion syndrome. Am. J. Obstet. Gynecol. 2013; 208(1): 3-18. DOI: https://doi.org/10.1016/j.ajog.2012.10.880
31. Lee H., Bebbington M., Crombleholme T.M. The North American Fetal Therapy Network Registry data on outcomes of radiofrequency ablation for twin-reversed arterial perfusion sequence. Fetal Diagn. Ther. 2013; 33(4): 224-9. doi: 10.1159 /000343223.
32. Abbasi N., Ryan G. Fetal primary pleural effusions: prenatal diagnosis and management. Best Pract. Res. Clin. Obstet. Gynecol. 2019; 58: 66-77. https://doi.org/10.1016/ j.bpobgyn.2019.01.005.
33. Shenker L. Fetal cardiac arrhythmias. Obstet. Gynecol.Surv. 1979; 34: 561-72. PMID: 384305
34. Kleinman C.S., Nehgme R.A. Cardiac arrhythmias in the human fetus. Pediatr. Cardiol. 2004; 25(3): 234-51. DOI: 10,1007 / s00246-003-0589-х
35. Jaeggi E., Ohman A. Fetal and neonatal arrhythmias. Clin. Perinatol. 2016; 43(1): 99-112. doi: 10.1016 / j.clp.2015.11.007
36. Sridharan S., Sullivan I., Tomek V., Wolfenden J., Škovránek J., Yates R., et al. Flecainide versus digoxin for fetal supraventricular tachycardia: comparison of two drug treatment protocols. Heart Rhythm. 2016; 13(9): 1913-9. doi: 10.1016 /j.hrthm.2016.03.023.
37. Krapp M., Kohl T., Simpson J.M., Sharland G.K., Katalinic A., Gembruch U. Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia. Heart. 2003; 89(8): 913-7. DOI: 10.1136 / heart.89.8.913
38. van Engelen A.D., Weijtens O., Brenner J.I., Kleinman C.S., Copel J.A.,Stoutenbeek P., Meijboom E.J. Management outcome and follow-up of fetal tachycardia. J. Am. Coll. Cardiol. 1994; 24(5): 1371-5. DOI: 10,1016 / 0735-1097 (94) 90122-8
39. Alsaied T., Baskar S., Fares M., Alahdab F., Czosek R.J., Murad M.H., et al. First-line antiarrhythmic transplacental treatment for fetal tachyarrhythmia: a systematic review and meta-analysis. J. Am. Heart Assoc. 2017; 6(12).pii: e007164.
40. Беспалова Е.Д., Суратова О.Г., Бокерия Е.Л., Бартагова М.Н., Гасанова Р.М., Тюменева А.И. Диагностика и лечение кардиальной патологии у плода. Бокерия Л.А., ред. М.: Научный центр сердечно-сосудистой хирургии РАМН, 2015. 244 с. [Bespalova E.D., Suratova O.G., BokerijaE.L., Bartagova M.N., Gasanova R.M., Tjumeneva A.I. Diagnostika i lechenie kardial’noj patologii u ploda. Bokerija L.A., red. M.: Nauchnyj centr serdechno-sosudistoj hirurgii RAMN, 2015. 244 s. (In Russian)].
41. Бокерия Е.Л., Беспалова Е.Д., Суратова О.Г. Фетальные органические тахиаритмии: опыт лечения. Анналы аритмологии. 2011; 2: 36-44.[Bokerija E.L., Bespalova E.D., Suratova O.G. Fetal’nye organicheskie tahiaritmii: opyt lechenija. Annaly aritmologii. 2011; 2: 36-44.(In Russian)].
42. Moise K.J. The usefulness of middle cerebral artery Doppler assessment in the treatment of the fetus at risk for anemia. Am. J. Obstet. Gynecol. 2008; 198(2): 161-4. e1-4. doi: 10.1016 / j.ajog.2007.10.788.
43. Weisz B., Rosenbaum O., Chayen B., Peltz R., Feldman B., Lipitz S. Outcome of severely anaemic fetuses treated by intrauterine transfusions. Arch. Dis. Child. Fetal Neonatal Ed. 2009; 94(3): F201-4. doi: 10.1136 /adc.2008.143560.
44. Leruez-Ville M., Ghout I., Bussières L., Stirnemann J., Magny J.F., Couderc S. et al. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am. J. Obstet. Gynecol. 2016; 215(4): 462. e10. doi: 10.1016 / j.ajog.2016.04.003
45. Jacquemard F., Yamamoto M., Costa J.M., Romand S., Jaсqz-Aigrain E., Dejean A. et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG. 2007; 114(9): 1113-21. DOI: 10,1111 / j.1471-0528.2007.01308.x
46. Welz J., Muller A., Gembruch U., Geipel A. Intrauterine Therapie der fetalen CMV Infektion mit Valganciclovir, eine Falldarstellung. Geburtshilfe Frauenheilkd. 2016; 76(10): CR004. DOI: 10.1055/s-0036-1593310
47. Crane J., Mundle W., Boucoiran I.; MATERNAL FETAL MEDICINE COMMITTEE. Parvovirus B19 infection in pregnancy. J Obstet. Gynaecol. Can. 2014; 36(12): 1107-16. doi: 10.1016 / S1701-2163 (15)30390-X.
48. Berger V.K., Sparks T.N., Jelin A.C., Derderian C., Jeanty C., Gosnell K. et al. Non-immune hydrops fetalis: do placentomegaly and polyhydramnios matter? J. Ultrasound Med. 2018; 37(5): 1185-91. doi: 10.1016 / S1701-2163 (15) 30390-X.
49. Huhta J.C. Guidelines for the evaluation of heart failure in the fetus with or without hydrops. Pediatr. Cardiol. 2004; 25(3): 274-86. DOI: 10,1007 / s00246-003-0591-3
50. Braun T., Brauer M., Fuchs I., Czernik C., Dudenhausen J.W., Henrich W., Sarioglu N. Mirror syndrome: a systematic review of fetal associated conditions, maternal presentation and perinatal outcome. Fetal Diagn. Ther. 2010; 27(4): 191-203. doi: 10.1159 / 000305096
51. Gedikbasi A., Oztarhan K., Gunenc Z., Yildirim G., Arslan O., Yildirim D.,Ceylan Y. Preeclampsia due to fetal non-immune hydrops: mirror syndrome and review of literature. Hypertens. Pregnancy. 2011; 30(3): 322-30.doi: 10.3109 / 106419509033232

Received 22.03.2019

Accepted 19.04.2019